Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease.
Identifieur interne : 001130 ( Main/Exploration ); précédent : 001129; suivant : 001131Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease.
Auteurs : Mélanie Bourque [Canada] ; Dean E. Dluzen ; Thérèse Di PaoloSource :
- Frontiers in neuroendocrinology [ 1095-6808 ] ; 2012.
English descriptors
- KwdEn :
- 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine, Animals, Estrogens (pharmacology), Gonadal Steroid Hormones (pharmacology), Humans, Models, Biological, Neuroprotective Agents (pharmacology), Parkinson Disease (genetics), Parkinson Disease (prevention & control), Parkinson Disease (psychology), Parkinsonian Disorders (chemically induced), Parkinsonian Disorders (pathology), Receptors, Estrogen (genetics), Receptors, Estrogen (metabolism), Receptors, Estrogen (physiology), Selective Estrogen Receptor Modulators (pharmacology), Signal Transduction (drug effects), Signal Transduction (genetics), Signal Transduction (physiology).
- MESH :
- chemical , genetics : Receptors, Estrogen.
- chemical , metabolism : Receptors, Estrogen.
- chemical , pharmacology : Estrogens, Gonadal Steroid Hormones, Neuroprotective Agents, Selective Estrogen Receptor Modulators.
- chemical , physiology : Receptors, Estrogen.
- chemical : 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
- chemically induced : Parkinsonian Disorders.
- drug effects : Signal Transduction.
- genetics : Parkinson Disease, Signal Transduction.
- pathology : Parkinsonian Disorders.
- physiology : Signal Transduction.
- prevention & control : Parkinson Disease.
- psychology : Parkinson Disease.
- Animals, Humans, Models, Biological.
Abstract
Studies with the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal model of Parkinson's disease have shown the ability of 17β-estradiol to protect the nigrostriatal dopaminergic system. This paper reviews the signaling pathways mediating the neuroprotective effect of 17β-estradiol against MPTP-induced toxicity. The mechanisms of 17β-estradiol action implicate activation of signaling pathways such as the phosphatidylinositol-3 kinase/Akt and the mitogen-activated protein kinase pathways. 17β-estradiol signaling is complex and integrates multiple interactions with signaling molecules that act to potentiate a protective effect. 17β-estradiol signaling is mediated via estrogen receptors, including GPER1, but others receptors, such as the IGF-1 receptor, are implicated in the neuroprotective effect. Glial and neuronal crosstalk is a critical factor in the maintenance of dopamine neuronal survival and in the neuroprotective action of 17β-estradiol. Compounds that stimulate GPER1 such as selective estrogen receptor modulators and phytoestrogens show neuroprotective activity and are alternatives to 17β-estradiol.
DOI: 10.1016/j.yfrne.2012.02.003
PubMed: 22387674
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000A86
- to stream PubMed, to step Curation: 000A86
- to stream PubMed, to step Checkpoint: 000A86
- to stream Ncbi, to step Merge: 001077
- to stream Ncbi, to step Curation: 001077
- to stream Ncbi, to step Checkpoint: 001077
- to stream Main, to step Merge: 001151
- to stream Main, to step Curation: 001130
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease.</title><author><name sortKey="Bourque, Melanie" sort="Bourque, Melanie" uniqKey="Bourque M" first="Mélanie" last="Bourque">Mélanie Bourque</name><affiliation wicri:level="1"><nlm:affiliation>Molecular Endocrinology and Genomic Research Center, Centre de recherche du CHUQ (CHUL), Quebec City, QC, Canada G1V 4G2.</nlm:affiliation><country>Canada</country><wicri:regionArea>Molecular Endocrinology and Genomic Research Center, Centre de recherche du CHUQ (CHUL), Quebec City, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Dluzen, Dean E" sort="Dluzen, Dean E" uniqKey="Dluzen D" first="Dean E" last="Dluzen">Dean E. Dluzen</name></author><author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2012">2012</date><idno type="RBID">pubmed:22387674</idno><idno type="pmid">22387674</idno><idno type="doi">10.1016/j.yfrne.2012.02.003</idno><idno type="wicri:Area/PubMed/Corpus">000A86</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A86</idno><idno type="wicri:Area/PubMed/Curation">000A86</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A86</idno><idno type="wicri:Area/PubMed/Checkpoint">000A86</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A86</idno><idno type="wicri:Area/Ncbi/Merge">001077</idno><idno type="wicri:Area/Ncbi/Curation">001077</idno><idno type="wicri:Area/Ncbi/Checkpoint">001077</idno><idno type="wicri:Area/Main/Merge">001151</idno><idno type="wicri:Area/Main/Curation">001130</idno><idno type="wicri:Area/Main/Exploration">001130</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease.</title><author><name sortKey="Bourque, Melanie" sort="Bourque, Melanie" uniqKey="Bourque M" first="Mélanie" last="Bourque">Mélanie Bourque</name><affiliation wicri:level="1"><nlm:affiliation>Molecular Endocrinology and Genomic Research Center, Centre de recherche du CHUQ (CHUL), Quebec City, QC, Canada G1V 4G2.</nlm:affiliation><country>Canada</country><wicri:regionArea>Molecular Endocrinology and Genomic Research Center, Centre de recherche du CHUQ (CHUL), Quebec City, QC</wicri:regionArea><wicri:noRegion>QC</wicri:noRegion></affiliation></author><author><name sortKey="Dluzen, Dean E" sort="Dluzen, Dean E" uniqKey="Dluzen D" first="Dean E" last="Dluzen">Dean E. Dluzen</name></author><author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name></author></analytic><series><title level="j">Frontiers in neuroendocrinology</title><idno type="eISSN">1095-6808</idno><imprint><date when="2012" type="published">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term><term>Animals</term><term>Estrogens (pharmacology)</term><term>Gonadal Steroid Hormones (pharmacology)</term><term>Humans</term><term>Models, Biological</term><term>Neuroprotective Agents (pharmacology)</term><term>Parkinson Disease (genetics)</term><term>Parkinson Disease (prevention & control)</term><term>Parkinson Disease (psychology)</term><term>Parkinsonian Disorders (chemically induced)</term><term>Parkinsonian Disorders (pathology)</term><term>Receptors, Estrogen (genetics)</term><term>Receptors, Estrogen (metabolism)</term><term>Receptors, Estrogen (physiology)</term><term>Selective Estrogen Receptor Modulators (pharmacology)</term><term>Signal Transduction (drug effects)</term><term>Signal Transduction (genetics)</term><term>Signal Transduction (physiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Receptors, Estrogen</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Receptors, Estrogen</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Estrogens</term><term>Gonadal Steroid Hormones</term><term>Neuroprotective Agents</term><term>Selective Estrogen Receptor Modulators</term></keywords><keywords scheme="MESH" type="chemical" qualifier="physiology" xml:lang="en"><term>Receptors, Estrogen</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine</term></keywords><keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Signal Transduction</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Parkinson Disease</term><term>Signal Transduction</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Parkinsonian Disorders</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Signal Transduction</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Models, Biological</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Studies with the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) animal model of Parkinson's disease have shown the ability of 17β-estradiol to protect the nigrostriatal dopaminergic system. This paper reviews the signaling pathways mediating the neuroprotective effect of 17β-estradiol against MPTP-induced toxicity. The mechanisms of 17β-estradiol action implicate activation of signaling pathways such as the phosphatidylinositol-3 kinase/Akt and the mitogen-activated protein kinase pathways. 17β-estradiol signaling is complex and integrates multiple interactions with signaling molecules that act to potentiate a protective effect. 17β-estradiol signaling is mediated via estrogen receptors, including GPER1, but others receptors, such as the IGF-1 receptor, are implicated in the neuroprotective effect. Glial and neuronal crosstalk is a critical factor in the maintenance of dopamine neuronal survival and in the neuroprotective action of 17β-estradiol. Compounds that stimulate GPER1 such as selective estrogen receptor modulators and phytoestrogens show neuroprotective activity and are alternatives to 17β-estradiol.</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name><name sortKey="Dluzen, Dean E" sort="Dluzen, Dean E" uniqKey="Dluzen D" first="Dean E" last="Dluzen">Dean E. Dluzen</name></noCountry><country name="Canada"><noRegion><name sortKey="Bourque, Melanie" sort="Bourque, Melanie" uniqKey="Bourque M" first="Mélanie" last="Bourque">Mélanie Bourque</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001130 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001130 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:22387674
|texte= Signaling pathways mediating the neuroprotective effects of sex steroids and SERMs in Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:22387674" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |